Frontline Camrelizumab/Rivoceranib Combination Shows Promise in Unresectable HCC
Amit Mahipal, MD, discusses data on camrelizumab plus rivoceranib in advanced hepatocellular carcinoma as well as the phase 3 CARES-310 trial, which is currently enrolling patients to receive the combination.
United States Comunidad Autonoma De Cataluna Amit Mahipal Developmental Therapeutics Program University Hospitals Seidman Cancer Center Case Comprehensive Cancer Center
Source: onclive.com